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DNA ligase IV (LigIV) and Artemis are central compo-
nents of the nonhomologous end-joining (NHEJ)
machinery that is required for V(D)J recombination
and the maintenance of genomic integrity in
mammalian cells. We report here crystal structures
of the LigIV DNA binding domain (DBD) in both its
apo form and in complex with a peptide derived
from the Artemis C-terminal region. We show that
LigIV interacts with Artemis through an extended
hydrophobic surface. In particular, we find that the
helix a2 in LigIV-DBD is longer than in other mamma-
lian ligases and presents residues that specifically
interact with the Artemis peptide, which adopts a
partially helical conformation on binding. Mutations
of key residues on the LigIV-DBD hydrophobic
surface abolish the interaction. Together, our results
provide structural insights into the specificity of the
LigIV-Artemis interaction and how the enzymatic
activities of the two proteins may be coordinated
during NHEJ.
INTRODUCTION
The adaptive immune system gains its ability to recognize a
plethora of antigens by the generation of an extensive repertoire
of antigen receptors on B and T lymphocytes. These numerous
receptors are created by V(D)J recombination, a process during
which DNA double-strand breaks (DSBs) are repaired by the
nonhomologous end-joining pathway (NHEJ) (Lieber, 2010).
NHEJ is one of the major pathways for the repair of DSBs in
mammalian cells, playing not only a central role in V(D)J recom-
bination and class switch recombination (CSR), but also in the
repair of pathological DSBs generated by ionizing radiation
and other chemical and enzymatic damage. This pathway works
throughout the cell cycle and does not require the presence of
a homologous sister chromatid (Lieber, 2010).
DNA ligase IV (LigIV) is an essential factor for NHEJ (Grawun-
der et al., 1998). Mutations in LigIV lead to a rare disease called
the Lig4 syndrome, which is characterized by microcephaly,Cell Reradiosensitivity, growth and developmental delay, and immuno-
deficiency (Chistiakov, 2010). Moreover, it has been shown that
in mice the absence of LigIV increases tumor generation in non-
lymphoid tissues (Sharpless et al., 2001).
LigIV is unique among other mammalian ligases in its ability to
perform nuclear DNA DSB repair (Simsek et al., 2011). It exhibits
a high degree of similarity with LigI and LigIII, particularly at the
level of domain organization of the catalytic core (Ellenberger
and Tomkinson, 2008). Thus, its unique ability to repair DSB
might be partly delineated through its interacting partners. LigIV
directly interacts with XRCC4 (Critchlow et al., 1997; Grawunder
et al., 1997) and Ku (Chen et al., 2000; Nick McElhinny et al.,
2000), and indirectly with DNA-PKcs (Drouet et al., 2005), Cer-
nunnos-XLF (Ahnesorg et al., 2006), and the MRN complex
(Chen et al., 2001), all which are necessary for NHEJ in mamma-
lian cells. Recently, we identified Artemis as a new interaction
partner of LigIV (Malu et al., 2012). Artemis, in complex with
DNA-PKcs, has a diverse array of nuclease activities and is
a necessary factor for the processing of DSBs during NHEJ
(Ma et al., 2002, 2005b). Association-binding experiments indi-
cate that the C-terminal region (C-ter) of Artemis directly inter-
acts with the DNA binding domain (DBD) of LigIV (LigIV-DBD).
Moreover, deletion analysis of Artemis C-ter identified an 11
amino acid peptide (485-DVPQWEVFFKR-495) that contains
the minimal interacting region. Aromatic residues in this region
are crucial for the interaction and are important for efficient
V(D)J recombination (Malu et al., 2012). However, the corre-
sponding interacting surface on LigIV-DBD remains uncharac-
terized due to the limited structural information for LigIV. As
such, it is unclear how the interaction between Artemis C-ter
and LigIV is mediated and how it facilitates NHEJ in mammalian
cells.
We report here crystal structures of the LigIV-DBD in both its
apo form and in complex with a peptide derived from the Artemis
C-ter. We show that LigIV-DBD interacts with Artemis through
a hydrophobic surface that is much more extended than in other
mammalian DNA ligases, such as LigI and LigIII. Based on the
structure, the interaction surface was further evaluated by
isothermal titration calorimetry (ITC) as well as by mutational
analysis of critical residues. Together, these results offer struc-
tural insights into the specificity of interaction between LigIV
and Artemis, important for development of the immune system
and genomic stability.ports 2, 1505–1512, December 27, 2012 ª2012 The Authors 1505
Figure 1. Crystal Structure of LigIV-DBD apo Form
(A) Ribbon diagram of LigIV-DBD. Secondary structure elements and impor-
tant amino acids side chains are labeled.
(B) Structural alignment of human Lig-DBDs. LigIV-DBD superimposed on
LigI-DBD (PDB ID code 1X9N, residues 284 to 531) and LigIII-DBD (PDB ID
code 3L2P, residues 168 to 375).
(C) Electrostatic surface representation of LigIV-DBD colored, with saturating
blue and red at +7 kT/e and 7 kT/e, respectively. A relatively uncharged and
exposed surface area on LigIV-DBD is highlighted by a dashed oval. Important
amino acids are labeled.
See also Figure S1.RESULTS
Structure of apo LigIV-DBD
The crystal structure of LigIV-DBD, determined at 2.8 A˚ resolu-
tion (Figure S1), is composed of two helical subdomains, related
by an2-fold axis (Figure 1A). The first subdomain is composed1506 Cell Reports 2, 1505–1512, December 27, 2012 ª2012 The Autof helices a1, a2, a3, a10, and a11 whereas the second subdo-
main consists of helices a4, a5, a6, a7, a8, and a9, and the two
are connected by long loops, L1 (71–86) and L2 (191–201). This
type of pseudo-symmetry is also observed in the DBDs of other
mammalian DNA ligases (Ellenberger and Tomkinson, 2008), as
well as in the C-terminal helix-hairpin-helix (HhH) domain of Es-
cherichia coli LigA (Lee et al., 2000), which is functionally similar
to the DBDof humanDNA LigIV. Aswith LigI and LigIII, the helical
subdomains in LigIV-DBD lend to both polar and nonpolar
surfaces (Figure S2). A superimposition of LigIV-DBD onto LigI/
DNA and LigIII/DNA complex structures is consistent with DNA
binding to the LigIV-DBD on its positively charged surface (Fig-
ure S2) (Cotner-Gohara et al., 2010; Pascal et al., 2004). In all,
even though the LigIV-DBD shares low sequence similarity
with the LigI (13% sequence identity) and LigIII (15% sequence
identity) DBDs (Figure S3), the structure is broadly similar, super-
imposing with root mean-square deviations (rmsd) of 4.1 A˚ (101
Cas) and 2.5 A˚ (157 Cas), respectively (Figure 1B).
The main difference between the LigIV-DBD and that of LigI
and LigIII is a substantially longer helix a2 (Figure 1B). The helix
is longer by approximately two turns compared to LigI and
by three full-turns when compared to LigIII (Figure 1B). This
extended portion of helix a2 supports an extended hydrophobic
surface characterized by partially solvent exposed residues on
both helices a2 (F42, W46, F49, and L53) and a1 (V10 and V14)
(Figure 1C). The presence of this hydrophobic surface and the
extension of helix a2 suggested that they could play a role in
the interaction with Artemis.
Structure of LigIV-DBD/cArt-Pep Complex
To understand the basis of specificity between LigIV and
Artemis, we determined the crystal structure of LigIV-DBD in
complex with a peptide derived from the C-ter of Artemis
(cArt-Pep) (Figures 2A and 2B). The structure, determined at
2.25 A˚ resolution, contains two complexes (A and B) in the asym-
metric unit, which superimpose with an rmsd of 0.54 A˚ (for 218
Cas). The cArt-Pep (485-DVPQWEVFFKR-495) is well defined
in complex A, with 10 of the 11 residues built into the electron
density map (Figure 2B). The cArt-Pep is less defined in complex
B, with three residues traced in the electron density map. We
describe below the structure of complex A.
The C-terminal portion of cArt-Pep adopts a helical conforma-
tion, supported by two intrachain hydrogen bonds (N488(O)-
V491(N)) and W489(O)-F493(N)). This helical portion of the
peptide fits into a shallow hydrophobic pocket on the surface
of LigIV-DBD, bordered by helices a2 and a1 (Figures 2C and
2D). The N-terminal region of the peptide (residues 485–488)
adopts an extended b-chain conformation that tracks the length-
ened portion of helix a2.
The hydrophobic pocket on LigIV-DBD is created by an
outward movement of helix a2, including a bending of the helical
axis at L43 by 20 (Figure 2B). This results in an outward
displacement of the helix a2 C terminus by 9 A˚, when com-
pared to the apo structure, and creates the space necessary to
bind cArt-Pep (Figure 2E). In addition to this gross movement
of helix a2, the side chain of F49 moves and reorients by several
Angstroms to create the cavity to accommodate W489 of cArt-
Pep (Figure 2E). Indeed, W489 is the most deeply buried residuehors
Figure 2. Crystal Structure of LigIV-DBD/cArt-Pep Complex
(A) A schematic of LigIV and Artemis domain organization and of regions that interact.
(B) Overall structure of the LigIV-DBD/cArt-Pep complex. LigIV-DBD (green) is represented in ribbon and cArt-Pep (pink) is represented in stick. Simulated
annealing 2Fo-Fc omit electron density is also shown for cArt-Pep, contoured at s = 1.0. The axis of helix a2 is marked by two straight lines to indicate the
bending.
(C) LigIV-DBD and cArt-Pep displayed separately to highlight the important amino acids.
(D) Electrostatic potential surface of LigIV-DBD and cArt-Pep when displayed separately.
(E) Superposition of apo (red) and peptide bound (green) forms of LigIV-DBD to show the movements in helix a2 (9 A˚) and residue F49. The peptide was omitted
for clarity.
(F) Detailed view of LigIV-DBD/cArt-Pep interaction surface. cArt-Pep and LigIV-DBD are shown in pink and green, respectively. The molecular surface of LigIV-
DBD is presented in gray. Hydrogen bonds are depicted in dashed yellow lines.
See also Figure S2.
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of cArt-Pep and it occupies roughly the position that F49 occu-
pied in the DBD apoenzyme. In addition to interactions with
F49, the indole ring ofW489 is involved in extensive hydrophobic
interactions with V10, V14, F42, and W46 (Figures 2D and 2F).
The F42, W46, and F49 aromatic rings pack in a herring-bone
pattern against W489. V10 and V14 stem from helix a1 and
they complete the hydrophobic cage around W489 of cArt-
Pep. A hydrogen bond (2.74 A˚) is also observed between the
nitrogen of W489 indole ring and the carbonyl group of D18 of
LigIV-DBD (Figure 2F). F492 and F493 are on the same side of
the helical portion of cArt-Pep as W489, and they too interact
with the hydrophobic pocket on the surface of LigIV-DBD; in
particular, with residues F42 and F49 on helix a2. In addition,
the main chain amide of F492 makes a direct hydrogen bond
with the side chain of S45. Supplementing these interactions
between W489, F492, and F493 on the helical portion of cArt-
Pep and the LigIV-DBD are van der Waals contacts between
P487 on the N-terminal extension of cArt-Pep and L53 from
the extended portion of helix a2 of LigIV-DBD (Figure 2F). Taken
together, LigIV and Artemis interact via an induced-fit mecha-
nism, wherein helix a2 in LigIV-DBD rotates outward to create
a hydrophobic pocket for binding a partially helical peptide
from the Artemis C-ter. The mainly hydrophobic nature of the
interaction is consistent with the stability of the complex at
high salt concentrations, up to 500 mM NaCl (data not shown).
Structural analysis of LigIV-DBD/cArt-Pep complex shows
that400 A˚2 of the LigIV-DBD surface area is buried at the inter-
face. To test the interface in solution, we used ITC. Consistent
with the crystal structure, wild-type LigIV-DBD binds the cArt-
Pep with a Kd of 4.8 mM and a binding stoichiometry of 1:1 (n =
1.0 ± 0.1) (Figure 3A). Mutations of F49 and F42 to alanine result
in a complete loss of peptide binding (Figures 3B and 3C),
consistent with the central role of these phenylalanines on helix
a2 in binding to the aromatic residues on cArt-Pep. By contrast,
amodest effect on binding is incurredwhenD18 and V14 on helix
a1 are mutated. D18 makes a hydrogen bond with the indole
nitrogen of W489 and a D18H mutation increases the Kd to
9.1 mM (Figure 3E), whereas a V14A mutation increases the Kd
to 13.64 mM (Figure 3F). Taken together, the ITC measurements
are consistent with the crystal structure in showing the dominant
role of F49 and F42 in binding the cArt-Pep.
To examine the role of F42 and F49 amino acids in context of
full-length proteins in vivo, we tested the ability of F42A and F49A
mutants to interact with Artemis by coimmunoprecipitation.
Consistent with the crystal structure and ITC measurements,
only wild-type LigIV interacted with Artemis. However, both the
wild-type and mutant LigIV interacted equally well with XRCC4
(Figure 3H). Together, these data provide further evidence that
LigIV interacts with Artemis and XRCC4 via mutually exclusive
surfaces: the DBD at the N terminus interacting with Artemis,
and the BRCT repeats at the C terminus engaging XRCC4 (Wu
et al., 2009).
Comparison to LigI and LigIII
Figure 1B shows the structure of LigIV-DBD superimposed on
the structures of LigI-DBD and LigIII-DBD. To examine whether
the LigI and LigIII DBDs can also bind cArt-Pep, we performed
florescence anisotropy (FA) peptide-binding experiments with1508 Cell Reports 2, 1505–1512, December 27, 2012 ª2012 The Autpurified DBDs. As shown in Figure 4A, LigI-DBD and LigIII-
DBD bind cArt-Pep with substantially lower affinity than LigIV.
Together, these in vitro results are in agreement with the coim-
munoprecipitation experiments (Malu et al., 2012), wherein
only LigIV-DBD was found to interact with Artemis. Figure 4B
shows the cArt-Pep modeled on the LigI-DBD and the LigIII-
DBD. In contrast to the LigIV-DBD, there is substantial steric
overlap between cArt-Pep and the LigI-DBD and LigIII-DBD.
Strikingly, the putative binding site in LigI-DBD is blocked by
its unique N-terminal ‘‘extension,’’ which coils around the poten-
tial binding site (Pascal et al., 2004). Also, as noted above,
helix a2 is shorter by approximately two turns in LigI-DBD, which
decreases the potential binding surface for cArt-Pep by 60 A˚2.
Finally, residues F49 and F42 that are essential for LigIV-DBD-
cArt-Pep interaction are substituted by smaller L315 and L322
in LigI DBD (Figure S3), which likely diminishes the van derWaals
interactions with W489 of cArt-Pep. In LigIII, because helix a2 is
shorter by three full-turns compared to LigIV there is no residue
equivalent to F49. Indeed, this region of LigIII is disordered in the
crystal structure (Figure 4B) (Cotner-Gohara et al., 2010). Taken
together, the LigIV-DBD differs from the LigI and LigIII DBDs in
presenting a hydrophobic surface that is adapted to bind the
C-terminal region of Artemis. Both the length of helix a2 and
the identity of specific residues on helix a2 contribute to the
specificity of LigIV-DBD-cArt-Pep interaction.
DISCUSSION
We present here molecular details of how LigIV and Artemis
interact. We show that LigIV recruits Artemis via a hydrophobic
surface that is more extended than in other mammalian DNA
ligases.Specifically, a helix (a2) inLigIVDBD is longer than inother
mammalian ligases and presents a set of hydrophobic residues
that interact selectively with the C-terminal region of Artemis.
Various models for NHEJ have been proposed in recent years,
from the sequential to the simultaneous recruitment of factors
to the DSB (Dobbs et al., 2010; Ma et al., 2005a; Yano et al.,
2009). The structure we present is consistent with the idea
that, in presence of Artemis, NHEJ factors are recruited simulta-
neously to a DSB, leading to the formation of a large complex.
Both Artemis and LigIV contain multiple domains and bind
other NHEJ factors. For example, in addition of LigIV, the
C-terminal region of Artemis also interacts with the kinase
DNA-PKcs, leading to both phosphorylation of Artemis and
autophosphorylation of the kinase itself (Goodarzi et al., 2006),
which promotes DNA-PKcs release from the DNA (Hammel
et al., 2010a). The N-terminal region of Artemis is composed of
a metallo-b-lactamase fold and forms the catalytic core for its
nuclease activity (Callebaut et al., 2002). In LigIV, the DBD at
the N terminus is followed by the catalytic adenylation domain
and an oligo-binding (OB) domain, whereas the C terminus con-
tains two BRCT repeats. The LigIV’s BRCT repeats are required
for interaction with XRCC4 (Sibanda et al., 2001;Wu et al., 2009),
which in turn recruits XLF (Cernunnos); a complex with a stoichi-
ometry of one BRCTs, two XRCC4, and two XLF can be isolated
by gel filtration (Hammel et al., 2010b). Intriguingly, from our
structure, the Artemis C-terminal region (or cArt-Pep) binds to
LigIV-DBD on the opposite face as the DNA, leaving thehors
Figure 3. LigIV-Artemis Interaction
(A–F) ITC titration profile of cArt-Pep with LigIV-DBDWT (A), LigIV-DBD F42A (B), LigIV-DBD F49A (C), LigIV-DBD F42AF49A (D), LigIV-DBD D18H (E), and LigIV-
DBD V14A (F).
(G) ITC profile for cArt-Pep dilution.
(H) Coimmunoprecipitation experiments with full-length and mutant LigIV. Flag IP was performed on lysates of 293T cells transfected with FNT (Flag-NLS-
Thioredoxin), Flag Ligase IV (FLLIV), or its point mutants FL42A and FL49Awith untagged Artemis.Western blot analysis for Flag, Artemis, and endogenous XRCC4
was performed. Levels of Artemis and XRCC4 in total cell extract (TCE) are shown as controls.
See also Figure S3.N-terminal nuclease domain of Artemis free to engage the DNA
substrate in conjunction with the catalytic domain of LigIV (Fig-
ure 4C). Such coordination of the nuclease and ligation activities
may help to increase the efficiency of the NHEJ reaction, though
this remains to be fully tested. XRCC4 and XLF lack enzymatic
activity but increase the efficiency of the ligation reaction (Graw-
under et al., 1997; Gu et al., 2007). From recent small-angle X-ray
scattering (SAXS) and crystallographic studies, XRCC4 and XLF
can form long filaments and may serve as ‘‘holders’’ of the DNACell Refor the ligation reaction (Hammel et al., 2010b, 2011; Ropars
et al., 2011). Although, a clearer picture of how the Artemis and
LigIV enzymatic activities are coordinated will emerge from a
structure of the complex with intact proteins, based on the cur-
rent structure one can begin to construct an initial model of how
Artemis and LigIV are recruited together to a DSB (Figure S4).
Along with other damage tolerance pathways, the NHEJ
machinery is potentially an important therapeutic target for
sensitizing tumor cells to chemotherapy and radiation treatmentports 2, 1505–1512, December 27, 2012 ª2012 The Authors 1509
Figure 4. Comparison of LigIV-DBD to LigI and LigIII
(A) Fluorescent anisotropy isothermal binding curves for cArt-Pep against LigIV-DBD, LigI-DBD, and LigIII-DBD. cArt-Pep binds specifically to LigIV-DBD.
Because of low affinity, LigI-DBD and LigIII-DBD could not be fully titrated against cArt-Pep and the Kds were not determined (ND).
(B) Close up views of LigIV-DBD/cArt-Pep binding (left panel) and models of cArt-Pep docked against LigI-DBD (center panel) and LigIII-DBD (right panel). Note
the steric overlap between cArt-Pep and the N-terminal region of LigI-DBD.
(C) A model of LigIV catalytic core bound to cArt-Pep (pink) and DNA substrate (orange). LigIV-DBD (green) and catalytic core (NTase and OBD) (light purple) are
represented as surfaces. The peptide binding site (yellow) and the DNA binding site are on opposite surfaces. A schematic of LigIV domain organization is shown
at the bottom.
See also Figure S4.
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(Lord and Ashworth, 2012). The LigIV-Artemis structure will aid in
the design of small molecule and peptidomimetic inhibitors for
increasing the vulnerability of tumor cells to chemotherapy and
radiation efficacy. The limited size of the LigIV-Artemis interface
and the fact that it is largely a solvent exposed hydrophobic
surface, in principle, should facilitate the design of chemical
inhibitors for the LigIV-Artemis interaction, analogous to PARP
inhibitors for the treatment of certain cancers (Hakimelahi
et al., 2001; Lord and Ashworth, 2012).
In conclusion, despite the central role of LigIV in V(D)J recom-
bination and DSB repair, there is limited structural information on
this key enzyme. The only atomic structures currently available
for LigIV are for BRCTs domains and a subdomain of the nucle-
otidyltransferase domain (Wu et al., 2009; Ochi et al., 2012), with
low-resolution electron microscopy (EM) and SAXS studies also
suggesting a degree of heterogeneity and/or flexibility when
intact LigIV interacts with XRCC4 (Recuero-Checa et al., 2009;
Hammel et al., 2010b). The atomic structures for LigIV-DBD we
present here reveal a unique DBD that has evolved to bind
both DNA and Artemis in a mutually exclusive manner.
EXPERIMENTAL PROCEDURES
Protein and Peptide Production
The native and Selenomethionine (SeMet) DNA binding domain of LigIV (LigIV-
DBD; residues 1–240) were expressed in E. coli. The proteins were purified by
nickel affinity chromatography, cation exchange chromatography, and size
exclusion chromatography. The DBDs of the human Ligase I (LigI, residues
260–535) and the human Ligase III (LigIII, residues 1–388) were expressed
and purified in the same manner as LigIV-DBD. cArt-Pep encompassing the
LigIV interaction motif (DVPQWEVFFKR) was synthesized by Bio-Synthesis
(Lewisville, TX).
Crystallization and Data Collection
LigIV-DBD was crystallized from solutions containing 16% PEG 3350 and
200 mM (NH4)3PO4 at 20
C. SeMet LigIV-DBD crystals were obtained under
similar conditions as the native protein except that (NH4)2SO4 replaced
(NH4)3PO4 in the crystallization mix. The LigIV-DBD/cArt-Pep cocrystals
were obtained from solutions containing 18% PEG 1000 and 200 mM Tris-
HCl pH 8.0. All crystals were cryo-protected in paratone-N oil (Hampton
Research), and flash cooled to 90K. All data sets were measured at the
Brookhaven National Laboratory (BNL; beamline X6A) and the Advanced
Photon Source (APS; beamline 24-ID). Due to significant anisotropy in LigIV-
DBD/cArt-Pep diffraction, the data were truncated and anisotropically scaled
by the Diffraction Anisotropy Server (Strong et al., 2006).
Structure Determination and Refinement
LigIV-DBD apo structure was solved by multiwavelength anomalous diffrac-
tion (MAD) phasing, followed by density modification. The initial model was
refined in program Phenix with strict geometric and B-factor restraints (Adams
et al., 2010), followed by several rounds of refinement that included simulated
annealing, energy minimization, geometry optimization, TLS refinement, and
manual rebuilding as needed. The final apo LigIV-DBD model contains 212
amino acids and 2 phosphate ions with an Rfactor of 21.7% and Rfree of
25.6% at 2.8 A˚ resolution (Table S1).
The structure of LigIV-DBD/cArtPep complex was solved by molecular
replacement by the program PHASER (McCoy et al., 2007), using the apo
LigIV-DBD as a search model. The structure was refined in the same manner
as the apo LigIV-DBD. The final model contains two LigIV-DBD/cArt-Pep
complexes in the asymmetric unit, complex A (aa 7–112 and 122–237 of
LigIV-DBD and aa 485–494 of Artemis) and complex B (aa 8–113 and 123–237
of LigIV-DBD and 487–489 of Artemis).
Interestingly, because of crystal contacts, helices a10 and a11 at the C
terminus take different paths in the apo LigIV-DBD and the LigIV-DBD/cArt-Cell RePep structures. The topology a10 and a11 in apo LigIV-DBD differs from
that observed in the LigI/DNA, LigIII/DNA, and LigIV/cArt-Pep crystal struc-
tures due to the crystal contacts these helices in apo LigIV-DBD structure
make with symmetry-related molecules.
Peptide Binding Experiments
Peptide binding experiments were performed by mixing 6-FAM (6-caboxy-
fluorescein)-labeled cArt-Pep (5 nM final concentration) with increasing con-
centrations of Lig-DBDs (0.1 nM–300 mM) in a peptide dilution buffer.
ITC Measurements
Calorimetric measurements were performed with the MicroCal ITC200 instru-
ment (GE Healthcare) in the temperature range of 5C–25C.
Transfections and Flag Immunoprecipitation from 293T Cells
HEK293T cells were transfected using the calcium phosphatemethod. Cellular
extracts were incubated with 200 mg/ml ethidium bromide at 4C. The cell
lysate (supernatant) obtained after centrifugation was used for Flag IP using
anti Flag M2-agarose beads (Sigma-Aldrich) and proteins were eluted with
0.2 mg/ml Flag peptide (Sigma-Aldrich) in Buffer C (150 mM KCl) (Ma et al.,
2002). Western blot analysis was performed at least two times from indepen-
dent transfections and representative results are shown.
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